Markets:

Overview

News

Currencies

International

Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

79.02 -0.63 (-0.79%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Revolution Medicines' Early-Data Validation For Cancer Program Wins Price Target Boost By This Analyst ↗

February 28, 2023

Via Benzinga

Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday ↗

February 28, 2023

U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 ↗

February 28, 2023

Via Benzinga

Revolution Medicines Earnings Preview ↗

February 24, 2023

Via Benzinga

Where Revolution Medicines Stands With Analysts ↗

December 14, 2022

Via Benzinga

Executives Buy More Than $12M Of 3 Stocks ↗

March 22, 2022

Although US stocks closed mostly lower on Monday, there were a few notable insider trades.

Via Benzinga

Insiders Buy More Than $19M Of 3 Stocks ↗

March 10, 2022

Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades.

Via Benzinga

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday ↗

December 08, 2022

U.S. stocks traded higher, with the Dow Jones jumping over 200 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration ↗

December 08, 2022

Via Benzinga

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

November 07, 2022

From Revolution Medicines, Inc.

Via GlobeNewswire

LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday ↗

August 12, 2022

WeTrade Group, Inc. (NASDAQ: WETG) jumped 46% to $20.56 after the company announced it entered into a sales agreement with Parkway Medical Limited to sell monkeypox virus test kits and antigen tests...

Via Benzinga

Earnings Scheduled For November 7, 2022 ↗

November 07, 2022

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

Via Benzinga

Earnings Outlook For Revolution Medicines ↗

August 08, 2022

Revolution Medicines (NASDAQ:RVMD) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.

Via Benzinga

$10 Million Bet On This Financial Services Stock? 3 Stocks Insiders Are Buying ↗

July 26, 2022

Although US stocks closed mixed on Monday, there were a few notable insider trades.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022 ↗

October 21, 2022

Upgrades

Via Benzinga

Revolution Medicines Stock Is Getting Hammered: Here's Why ↗

July 20, 2022

Revolution Medicines Inc (NASDAQ: RVMD) shares are trading lower by 11.25% to $21.82 Wednesday morning after the company announced the pricing of its underwritten public offering of 11,500,000 shares...

Via Benzinga

The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study ↗

July 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For August 9, 2022 ↗

August 09, 2022

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 20, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

July 20, 2022

Investors ready to start trading early this morning will want to check out the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 19, 2022

Gainers Talis Biomedical (NASDAQ:TLIS) shares moved upwards by 10.6% to $0.94 during Tuesday's after-market session. The company's market cap stands at $25.0 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022 ↗

May 20, 2022

Upgrades

Via Benzinga

Earnings Scheduled For May 9, 2022 ↗

May 09, 2022

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

Via Benzinga

Revolution Medicines's Earnings Outlook ↗

May 06, 2022

Revolution Medicines (NASDAQ:RVMD) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

7 Stocks That Insiders Are Buying Now. Should You? ↗

March 31, 2022

These stocks have seen big insider buying, but you may want to consider other factors before following suit.

Via InvestorPlace

Children's Place And 2 Other Stocks Bought By Insiders ↗

March 25, 2022

Although US stock futures traded higher this morning on Friday, there were a few notable insider trades.

Via Benzinga

Insiders Buy More Than $3B Of 4 Stocks ↗

March 07, 2022

Although US stock futures traded lower this morning amid rising Russia-Ukraine concerns, there were a few notable insider trades.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗

March 01, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.